Loading...
Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
Takeda Pharmaceutical’s recent $1.2 billion licensing agreement for a bispecific antibody in oncology could represent a landmark transaction in the drug development sector, highlighting the growing importance of bispecific antibodies in cancer treatment.
Takeda Pharmaceutical’s recent $1.2 billion licensing agreement for a bispecific antibody in oncology could represent a landmark transaction in the drug development sector, highlighting the growing importance of bispecific antibodies in cancer treatment.
READ MORE
The final special edition of The Readout from JPM 2026 brings key updates about leading biotech companies including Regeneron’s perspectives, IPO market outlook, and intensified focus on Johnson & Johnson.
The year 2026 is shaping up to be pivotal for rare disease drug development, with significant filings, approvals, and clinical readouts expected, highlighting the growing attention to this specialized sector.
AstraZeneca outlines its ambitious growth strategy targeting $80 billion in revenue by 2030, supported by innovative ADCs, cell therapies, and a pipeline of near-term product launches.
Novartis is deliberately abstaining from developing a GLP-1 drug, a decision explained by the company as a strategic move amid a saturated market of me-too GLP-1 therapies.
After a challenging year marked by mortality concerns, Sarepta Therapeutics is poised for a significant 2026 with promising siRNA programs targeting muscular dystrophies.
In response to impending patent expirations, Pfizer is expediting its lead obesity drug into Phase III with a targeted 2028 launch, underpinning its strategy to maintain growth and competitive positioning.
AbbVie has committed $650 million to acquire rights to a promising bispecific antibody targeting PD-1 and VEGF, expanding its footprint in the competitive oncology R&D landscape.
As the pharmaceutical industry predominantly centers on late-stage developments, Bristol Myers Squibb strategically invests in early-stage biopharma collaborations to build long-term innovation pipelines.
Alnylam, a leader in gene-silencing therapies, outlines an ambitious strategic plan for the next five years despite disappointing sales of its key drug, signaling a focus on innovation and growth.
Insmed’s newly approved bronchiectasis drug Brinsupri significantly outperformed sales forecasts in its first full quarter.
